The effect of biofeedback therapy in psychiatric rehabilitation

Improving clinical, cognitive, and psychosocial dysfunction in patients with schizophrenia: a neurofeedback study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN78612833

Enrollment

Registered

2021-05-18

Start date

2016-09-25

Completion date

Unknown

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Mental and Behavioural Disorders Schizophrenia

Interventions

Patients are randomly assigned to three groups: Group 1 receive standard rehabilitation interventions (n = 18) Group 2 receive a standard rehabilitation program according to an established schedule (

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with schizophrenia (DSM-5), residual, in partial remission for =1.5 years 2. Patient’s consent 3. Aged 18-65 years 4. Right-handedness

Exclusion criteria

Exclusion criteria: 1. Current neurological diseases 2. Mental disability 3. Alcohol or psychoactive substances addiction

Design outcomes

Primary

Measure	Time frame
Measured at the beginning of the study and after 3 months: 1. Psychopathological symptoms measured using the Positive and Negative Syndrome Scale (PANSS) 2. Cognitive and psychosocial performance measured using the Beck Cognitive Insight Scale (BCIS), Color Trails Test (CTT)-1, CTT-2, d2, Acceptance of Illness Scale (AIS) and General Self-efficacy Scale (GSES) 3. Biochemical markers e.g. serum level of brain-derived neurotrophic factor (BDNF) 4. Event-related potentials (ERP) and quantitative electroencephalography – neurofeedback-dependent (QEEG-NF)	—

Measure

Time frame

Measured at the beginning of the study and after 3 months: 1. Psychopathological symptoms measured using the Positive and Negative Syndrome Scale (PANSS) 2. Cognitive and psychosocial performance measured using the Beck Cognitive Insight Scale (BCIS), Color Trails Test (CTT)-1, CTT-2, d2, Acceptance of Illness Scale (AIS) and General Self-efficacy Scale (GSES) 3. Biochemical markers e.g. serum level of brain-derived neurotrophic factor (BDNF) 4. Event-related potentials (ERP) and quantitative electroencephalography – neurofeedback-dependent (QEEG-NF)

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Poland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026